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Solid-state NMRPhospholemman (PLM) is a single-span transmembrane protein belonging to the FXYD family of proteins. PLM
(or FXYD1) regulates the Na,K-ATPase (NKA) ion pump by altering its afﬁnity for K+ andNa+ and by reducing its
hydrolytic activity. Structural studies of PLM in anionic detergent micelles have suggested that the cytoplasmic
domain, which alone can regulate NKA, forms a partial helix which is stabilized by interactions with the charged
membrane surface. This work examines the membrane afﬁnity and regulatory function of a 35-amino acid
peptide (PLM38–72) representing the PLM cytoplasmic domain. Isothermal titration calorimetry and solid-state
NMRmeasurements conﬁrm that PLM38–72 associates stronglywithhighly anionic phospholipidmembranes, but
the association is weakened substantially when the negative surface charge is reduced to a more physiologically
relevant environment.Membrane interactions are alsoweakenedwhen thepeptide isphosphorylated at S68, one
of the substrate sites for protein kinases. PLM38–72 also lowers the maximal velocity of ATP hydrolysis (Vmax) by
NKA, and phosphorylation of the peptide at S68 gives rise to a partial recovery of Vmax. These results suggest that
the PLMcytoplasmicdomainpopulatesNKA-associated andmembrane-associated states indynamic equilibrium
and that phosphorylation may alter the position of the equilibrium. Interestingly, peptides representing the
cytoplasmic domains of two other FXYD proteins, Mat-8 (FXYD3) and CHIF (FXYD4), have little or no interaction
with highly anionic phospholipid membranes and have no effect on NKA function. This suggests that the
functional and physical properties of PLM are not conserved across the entire FXYD family.38–72, a peptide representing
ammary tumor protein; CHIF
ional-echo double-resonance;
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Regulation of ion transport, and in particular control of intracellular
calcium levels ([Ca2+]i), is essential to muscle function and maintenance
ofnormalpatternsof contractionandrelaxation. Calcium inﬂuxandefﬂux
is coupled to Na+ and K+ transport into and out of myocytes, and the
entire calcium cycling process is regulated synergistically by several
proteins including sarco-endoplasmic reticulum Ca2+-ATPase (SERCA),
Na+,K+-ATPase (NKA) and the Na+/Ca2+ exchanger (NCX1) [1,2]. NKA
and NCX1 are both regulated independently by the 72-residue
transmembrane (TM) protein phospholemman (PLM), which is widely
distributed in human tissues with expression highest in cardiac and
skeletal muscle [3–8]. Disruption of ionic ﬂuxes in cardiac muscle is a
contributing factor in heart failure (HF), and myocardial infarction,cardiomyopathy and cardiac hypertrophy all invoke changes in the
expression and functions of proteins thatmaintain the homeostatic norm.
PLMbelongs to a group of single-spanmembrane proteins known as
the FXYD family, named in recognition of their invariant Phe-X-Tyr-Asp
signature motif close to the N-terminus [9]. FXYD proteins appear to
regulate the rate of ion transport across cell membranes via an
association with ion pumps. PLM (or FXYD1) is one of at least four
members of the family believed to act as a tissue speciﬁc regulator of
NKA [6,10–12]. PLM associates speciﬁcally with the α1/β and α2/β
isoforms of NKA, resulting in a small decrease in external K+ afﬁnity and
a nearly two-fold decrease in the internal Na+ afﬁnity of the enzyme [6],
although the precise regulatory effect remains a matter of debate.
Regulation ofNKAappears to involve contacts between thehydrophobic
transmembrane domains of NKA and PLM, with additional interactions
in the cytoplasmic regions [13,14]. Measurement of whole-cell NKA
currents in the presence of water-soluble peptides representing the
19C-terminal residues of the cytoplasmic domain (PLM54–72) indicates
that the cytoplasmic domain alone is sufﬁcient to regulateNKA [15]. The
cytoplasmic domain of PLM is themajor plasmamembrane substrate for
protein kinase A (PKA) and protein kinase C (PKC) [16,17]. In cardiac
muscle, phosphorylation of PLM in the cytoplasmic domain, at S68alone
or at both S68 and S63, occurs following activation of either α or β
adrenergic receptors and correlates with an increase in contractility
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level above that in the absence of the peptide [15], providing a link
between kinase activation and pump modulation.
The three-dimensional structure of PLM in a lipid bilayer envi-
ronment is not knownand theprecise nature of its associationwithNKA
is also unclear, although structuralmodels have been proposed [18–20].
NMR structural analysis of PLM in SDS micelles identiﬁed two helical
segments in the cytoplasmic domain, including anamphipathic helixH4
from residues 59 to 70 which associates with the negatively charged
micelle surface and orients approximately perpendicular to the
transmembrane region [19,21,22]. Studies of a 35-amino acid peptide
representing the PLM cytoplasmic domain (PLM38–72) also revealed
strong interactions with the headgroups of negatively charged
phospholipids [23]. A recent study found that phosphorylation of PLM
at S68 does not alter signiﬁcantly the structure or dynamics of the
cytoplasmic domain in SDS micelles, and increases only slightly the
dynamics of the C-terminal helical segment [20]. In the same study it
was speculated that the membrane location of H4 allows it to be
positioned close to the end of transmembrane helix 10 of NKA, where it
could contribute to the network of positive charges constituting a
putative voltage-sensingmodule [20]. The extent towhich the structure
and dynamics of PLM in detergent micelles emulate its properties in a
lipid bilayer has not been established. In view of the functional role of
the PLM cytoplasmic domain, studies of its structural and dynamic
properties in the presence of lipid bilayers would provide useful new
insights into the properties of PLM.
Here we use isothermal titration calorimetry (ITC) and solid-state
NMR to examine the interactions of the peptide PLM38–72 (sequence
shown in Fig. 1) with phospholipid membranes of different head-group
composition. We show that the membrane afﬁnity of PLM38–72 is highly
dependent on membrane surface charge and is reduced after phosphor-
ylation of the peptide at S68. Both peptides lower the rate of ATP
hydrolysis by NKA in a kidney membrane preparation, but the S68
phosphorylated peptide has less pronounced inhibitory effect than
PLM38–72. Both peptides also lower the afﬁnity for ADP binding to the
high-afﬁnity nucleotide binding site. Peptides representing the cytoplas-
mic domains of two other FXYD family proteins, the 8 kDa mammary
tumor proteinMat-8 (FXYD3) and the corticosteroid induced factor CHIF
(FXYD4), have much lower membrane afﬁnities than PLM38–72 and do
not affect NKA activity, suggesting that there is variability in the physical
and functional properties amongst the FXYD family members.
2. Methods and materials
2.1. Materials
Synthetic analogues of the human PLM,Mat-8 and CHIF cytoplasmic
domains were purchased in pure form (N95%) from Peptide ProteinFig. 1. Primary sequences of human PLM (FXYD1), Mat-8 (FXYD3) and CHIF (FXYD4). Highl
and residues corresponding to the peptides studied here (bold). Below each sequence are
regions (H1–H4) determined by solution-state NMR [20–22].Research Ltd (Fareham, U.K.). PLM38–72 and the S68-phosphorylated
derivative (pPLM38–72) were N-terminally acetylated in order to
mimic the internal peptide bond. One batch of PLM38–72 was
uniformly labeled with 13C and 15N at residues R61, R65, R66 and
R67 ([13C,15N]PLM38–72). In addition a shorter cytoplasmic fragment
(PLM63–72) and an N-terminal extracellular fragment (PLM1–12)
containing the FXYD sequence were also prepared. The C-terminus
of PLM1–12 was amidated to mimic the internal peptide bond of full-
length PLM. pPLM38–72 was synthesized using the appropriate fmoc-
protected phosphoserine precursor and 100% incorporation of the
phosphate group was conﬁrmed by electrospray mass spectroscopy
and 1H and 31P NMR spectroscopy.
L-α-Dioleoylphosphatidylcholine (DOPC), L-α-dimyristoylpho-
sphatidyl-choline (DMPC), L-α-dioleoylphosphatidylserine (DOPS),
L-α-dioleoyl-phosphatidylglycerol (DOPG), and all other chemicals
were purchased from Sigma Chemicals Ltd (UK). [14C]ADP with a
speciﬁc radioactivity of about 2·109Bq/mmol was obtained fromNew
England Nuclear (USA).2.2. Preparation of Na,K-ATPase
Membranous NKA from pig kidney microsomal membranes was
prepared using SDS and puriﬁed by differential centrifugation to a
speciﬁc activity of about 30 μmol ATP hydrolyzed/mg protein per min
at 37 °C [24,25]. Stock solutions of the enzyme were stored at about
5 mg protein/ml in 20 mMhistidine, 1 mM EDTA and 250 mM sucrose
(pH 7.0). Renal NKA co-puriﬁes with the γ-subunit protein (FXYD2),
which is homologous to PLM in the transmembrane domain but lacks
the extended cytoplasmic region of PLM. For this latter reason it was
assumed that functional effects of PLM38–72 would not be masked by
the presence of the γ-subunit, although this possibility cannot be
ruled out.2.3. NKA activity measurements
Enzymatic activities and protein contents were determined as
described previously [26]. Here, assays of Na+-activation of steady-
state NKA activities (at 37 °C, pH 7.4, with 20 mM KCl, 3 mM ATP and
4 mM MgCl2 in the assay medium) were performed by measuring
phosphate liberation from ATP with colorimetric methods [27,28].
Inclusion of 1 mM ouabain served as a background control. The NKA
concentration was 0.4 μg/ml and the concentration of PLM-peptide
was 0.1 mM. The incubation with ATP lasted 15 min. PLM-peptides
were solubilized in 10 mM histidine (pH 7.0) and kept at 20 °C for
120 min before use. The pH of the assay mediumwas not altered after
the addition of any of the PLM peptides to 0.1 mM.ighted are the FXYD sequence (italics), predicted transmembrane domain (underlined)
secondary structure proﬁles showing the approximate length and position of helical
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Equilibrium binding of nucleotides was measured in double-
labeling ﬁltration experiments essentially as previously described
[29]. A 0.25 ml volume of a solution containing 0.2 mg/ml of NKA in
buffer (30 mM NaCl, 10 mM histidine (pH 7.0) and 0.65 mM CDTA)
with 0.05–45 μM [14C]ADP, [3H]glucose and 0 or 0.1 mM PLM was
loaded on two stacked Millipore HAWP 0.45 μm ﬁlters; the enzyme
remained adsorbed on the top ﬁlter, while the bottom one served as a
control. The ﬁlters were separately counted in 4 ml Packard
Filtercount scintillation ﬂuid. The amount of nucleotide bound to
the protein was calculated by subtracting from the total amount of
nucleotide on the (top) ﬁlter (bound plus unbound nucleotide) the
amount of unbound nucleotide, trapped in the ﬁlter together with the
wetting ﬂuid; the amount of unbound nucleotide was also propor-
tional to the amount of [3H]glucose in the same ﬁlter. Curve ﬁtting for
the nucleotide binding was performed using Origin 6.0 software
(Microcal, Amherst, CA). Parameters derived are given with standard
deviations.
2.5. Preparation of vesicles
Small unilamellar vesicles (SUVs) were prepared from DOPC alone
or from binary DOPC/DOPS mixtures in 1:1, 2:1, 4:1 or 9:1 molar
ratios. SUVs of 2:1 DMPC/DOPS and 2:1 DMPC/DOPG were also
prepared. Lipids were prepared in chloroform and then dried under
nitrogen and high vacuum, before resuspension in either 10 mM
phosphate, pH 7, or 10 mM Tris, 1 mM EDTA, pH 7.4, with or without
30 mM NaCl. Sonication was carried out for 2–3 min on ice, using a
Dawe Ultrasonic probe sonicator (London) at 50% duty cycle, output
control 5, to promote formation of SUVs.
2.6. Isothermal titration calorimetry
Heat ﬂow resulting from peptide binding to lipid vesicles was
measured using the high-sensitivity standard VP-ITC or the ultrasensi-
tive iTC200 MicroCalorimeter (MicroCal LLC, Northampton, MA).
Reaction cell volume and total injection volume were respectively,
1.4448 ml and 279.5 μl for the VP-ITC and 200 and 40 μl for the iTC200.
Experiments were performed at 25 °C, at a power reference setting of
15 μcal/s (VP-ITC), or 6 μcal/s (iTC200)with stirring at 307 rpm(VP-ITC),
or 1000 rpm (iTC200). Prior to use all solutions were degassed under
vacuum. Data analysis was carried out using the Origin v.7 software
(MicroCal). Experimental conditions were designed following estab-
lished protocols [30–32]. The reaction cell contained either a 50 μM
(VP-ITC), or a 100 μM (iTC200), solution of peptide (PLM38–72 or
pPLM38–72), in 10 mM Tris; 1 mM EDTA, pH 7.4. A 10 mM suspension
of lipid SUVs was prepared in the same buffer and injected via the
syringe. Titrations were carried out at intervals up to 10 min in 10 μl
(VP-ITC), or 0.5 and 1 μl (iTC200), aliquots following an initial discard
aliquot of 3 μl (VP-ITC), or 0.3 μl (iTC200). Each injection generates a
heat of reaction, determined by integration of the individual peaks
from the heat ﬂow trace. The heat of dilution was determined in
controls experiments whereby lipid vesicles were titrated in to a
buffer solution minus the peptide. Subtraction of the heat of dilution
values from experimental values allows the determination of heat
ﬂow resulting from peptide binding to lipid.
2.7. Far UV circular dichroism
Secondary structural measurements of peptides were carried out
on a Jasco J-180 spectropolarimeter. CD spectra were recorded from
250 to 195 nmusing a 0.1 cm cuvette, a scan rate of 20 nm/min and an
average of 4 accumulations per sample for triﬂuoroethanol (TFE)
titrations and 8 accumulations for lipid titrations. All peptides were
prepared to 50 μM in 10 mM phosphate, pH 7. Initial measurementswere made using a stepwise titration with TFE to generate measure-
ments up to 40% TFE. The experimentwas then repeated titrating with
SUVs of 50 mM DMPC/DOPG (2:1) resulting in lipid/peptide molar
ratios of 50:1, 75:1, and 100:1. In each case controls were carried out
by titrating TFE or SUVs into buffer minus the peptides and deducting
the values obtained from the experimental values. The percentage
α-helical content was calculated using the following equation [33]:
%helix = 100 × θobs−θCð Þ= θH−θCð Þ ð1Þ
where θH=−40000×(1−x/n)+100T and θC=640−45T. The
quantities θH and θC represent the molar ellipticity values for 100%
α-helix and 100% random coil, respectively, both expressed in deg.
cm2/dmol. The quantity θobs is the observed molar ellipticity
measured at 222 nm, T is the temperature in °C, N is the number of
amino acids, and x is a constant set at 2.5, which corrects for non-
hydrogen bonded carbonyl groups.
2.8. NMR sample preparation
For solid-state NMR analysis of membrane-peptide interactions,
50 mg 2:1 DMPC/DOPG or 50 mg DOPC was dissolved in chloroform
and dried to a ﬁlm under nitrogen and high vacuum. The lipids were
then resuspended in 50 μl of 10 mM phosphate with 1 mM EDTA at
pH 7.4. Once NMR measurements had been carried out on the lipid
control samples, peptide was added in 4 and 6 μl consecutive aliquots
to give the desired ﬁnal lipid to peptide molar ratio. Following
addition of peptide, each sample was subject to 5 cycles of freeze/
thawing and vortexed thoroughly before transferring to a 4 mm
diameter zirconia MAS rotor or 5 mm sample tube.
2.9. Solid-state NMR measurements
Spectra were recorded on a Bruker Avance 400 MHz spectrometer
operating at frequencies of 400.13 MHz for 1H and 100.16 MHz for 13C.
All spectra were obtained with a Bruker variable temperature triple-
resonance MAS probehead, with samples packed into a 4 mm
diameter zirconium rotor. Cross-polarization magic-angle spinning
(CP-MAS) 13C SSNMR spectra were recorded at a sample rotation rate
of 8 kHz. Hartmann-Hahn cross-polarization from 1H to 13C was
achieved at a proton ﬁeld of 66 kHz. Spectra were obtained by
accumulating 50,000–70,000 transients with a 1.5-s recycle delay.
Site-speciﬁc peptide-membrane interactions were monitored in a
13C-observe, 31P-dephase rotational-echo double-resonance (13C(31P)
REDOR) SSNMR experiment [34] at a sample spinning rate of 5300 Hz.
Two spectra were recorded. In the ﬁrst, dipolar dephasing was
achieved with a train of 8-μs 180° pulses at the 31P frequency twice
every sample rotation period (with xyxyyxyx phase cycling) and a
single 8-μs 180° pulse at the 13C frequency in the centre of the
dephasing period to refocus isotropic 13C chemical shifts. The total
dephasing period was 5.4 ms. Continuous wave proton decoupling at
100 kHz was applied during the dephasing period and two-phase
phase-modulated (TPPM) decoupling [35] at the same ﬁeld was
applied during acquisition. A second control (“full-echo”) spectrum
was obtained under identical conditions to the ﬁrst, except that the
31P dephasing pulses were omitted. Both spectra required the
accumulation of 180,000 transients with a 1.5-s recycle delay,
requiring a total experimental time of 6.25 days. The ﬁnal spectra
were the result of accumulating blocks of 20,000 transients,
interleaved between control and dephased spectra to average the
effects of drifts in tuning across both spectra. The REDOR spectra were
collected at −30 °C and all other spectra were collected at 4 °C. The
lower temperature was necessary for the REDOR measurements to
eliminate molecular dynamics, which would otherwise average the
weak 13C-31P dipolar couplings and attenuate dephasing. All spectra
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(50 Hz line broadening) prior to Fourier transformation.
3. Results
3.1. Afﬁnity of PLM peptides for phospholipid bilayers
ITC was used to monitor the thermodynamic parameters associ-
ated with the binding of PLM38–72 and pPLM38–72 to vesicles of
different phospholipid mixtures. The peptides were titrated with
phospholipid SUVs until the peptide in the reaction cell was bound
completely to the membranes and no further heat ﬂow occurred. This
procedure allows the total binding enthalpy ΔHtot to be measured,
from which a binding isotherm can be plotted and an apparent
dissociation constant (KDapp) calculated for the peptide [30–32,36,37].
First, experiments were carried out to compare the afﬁnities ofFig. 2. ITC measurements of PLM38–72 interactions with phospholipid membranes of differen
(25 to 50 μM lipid per injection) composed of DOPC and DOPS inmolar ratios of 1:1 (a), 2:1 (
enthalpic data following subtraction of the heat of dilution for the peptide. The data were ﬁtt
for PLM38–72 is plotted as a function of DOPC/DOPS membrane surface charge (f).unphosphorylated PLM38–72 for membranes of zwitterionic DOPC and
anionic DOPS bearing different surface charge, conferred by varying
the proportions of the two lipids. Raw enthalpic data for DOPC/DOPS
injections into PLM38–72 at an ionic strength of 30 mM NaCl indicated
that the lipid–peptide interaction is exothermic (data not shown).
Corresponding plots of enthalpy changes (ΔHk) per mole of peptide,
expressed as a function of lipid/peptide molar ratio (i.e., for each
injection k of lipid into the cell), are shown for SUVs of different DOPC/
DOPS composition in Fig. 2a to e. The total binding enthalpy
(ΔHtot=∑ΔHk) for the peptide increases with membrane surface
charge, from virtually zero for pure DOPC to 723 kcal/mol for 1:1
DOPC/DOPS (Fig. 2f). In parallel, fewer lipid injections are required to
achieve saturation of the membranes by the peptide. A semi-
quantitative measure of afﬁnity is obtained by transforming the
calorimetric data into a binding isotherm expressing themolar ratio of
membrane-bound peptide per lipid (Xb) as a function of thet surface charge. Heat ﬂows are shown for 100 μM PLM38–72 titrated with lipid vesicles
b), 4:1 (c), 9:1 (d) and for DOPC alone (e). Curves were generated by integrating the raw
ed by the MicroCal ‘one set of sites’ function (black lines). Total binding enthalpy (ΔHtot)
Fig. 3. Afﬁnity of PLM38–72 for DOPC/DOPS membranes bearing different surface charge.
ITC binding isotherms are shown for PLM38–72 titrated with 1:1 DOPC/DOPS (squares),
2:1 DOPC/DOPS (up triangles), 4:1 DOPC/DOPS (circles) and 9:1 DOPC/DOPS (down
triangles). Solid lines represent the best ﬁts to the data obtained with Eq. (2).
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(CF) [32,38–40]. By assuming a simple single-site binding model an
apparent dissociation constant (KDapp) can be estimated with the
equation:
Χb =
Χsatb :CF
CF + K
app
D
ð2Þ
A more rigorous analysis of peptide-membrane interactions
requires knowledge of the membrane surface potential, which can
be estimated from the surface charge density using Gouy-Chapman
theory [38]. The more simple approach in Eq. (2) is sufﬁcient to
observe trends in the relative afﬁnity of a single peptide for different
membranes, or to compare the afﬁnities of phosphorylated and non-
phosphorylated variants of the same peptide for the same lipid
systems [38]. Binding isotherms for PLM38–72 titrated with different
DOPC/DOPS membranes are shown in Fig. 3 and Table 1 summarizes
the values of KDapp and the binding capacity (expressed as the moles of
peptide bound per mole of lipid at saturation). The membrane afﬁnity
of PLM38–72 decreases by almost two orders of magnitude when the
negative surface charge is reduced from 33% (i.e. 2:1 DOPC/DOPS) to
10% (i.e., 9:1 DOPC/DOPS), and the binding capacity is also reduced
substantially. The 9:1 DOPC/DOPS is representative of eukaryotic cells,
in which the cytoplasmic leaﬂet of the plasma membrane contains
approximately 10–15% anionic lipids. For instance, microsomes from
kidney outer medulla contain approximately 8% phosphatidylserineTable 1
Summary of binding capacity (Χbsat, expressed as mole peptide per mole lipid) and apparent d
with PLM38–72 and pPLM38–72. A correction factor of 0.6 was applied in the calculations, sin
Membrane PLM38–72
Χbsat (mol/mol) KDapp (M−1)
1:1 DOPC/DOPSa 0.153 –
2:1 DOPC/DOPSb 0.092 (0.011) 7.51 (2.30)×
4:1 DOPC/DOPS 0.068 9.18×10−6
9:1 DOPC/DOPS 0.020 8.11×10−5
DOPC Enthalpy changes are below level of detection
2:1 DMPC/DOPSb 0.136 (0.053) 3.67 (2.13)×
2:1 DMPC/DOPGb 0.232 (0.049) 3.07 (1.79)×
a Binding isotherm does not conform to ideal Eq. (2). Χbsat is therefore an approximate va
b Isotherms measured in triplicate. Mean values are given with standard deviations in paand 7% phosphatidylinositol as the major anionic lipids [41].
Interestingly, the isotherm for 1:1 DOPC/DOPS and, to a lesser degree,
the isotherm for 2:1 DOPC/DOPS, deviate from the best ﬁtting curve
generated with Eq. (2) (Figs. 2a, b and 3). The origin of this non-ideal
behavior is not known at this stage, but an alternative analytical
model will be required to interpret these binding isotherms more
accurately. One possible explanation is that the peptide induces
lateral phase separation of the zwitterionic and anionic lipids at high
DOPS concentrations. Previous 2H wide-line and 31P MAS NMR
measurements of PLM37–72 interactions with 2:1 DMPC/DOPG
membranes were consistent with such a phenomenon [23].
The effect of phosphorylation at S68 on the membrane afﬁnity of
PLM38–72 was investigated by ITC experiments inwhich peptides were
titrated with membranes bearing the same negative surface charge
(33%) but differing in the hydrocarbon chain content (C18 unsatu-
rated dioleoyl or C14 saturated dimyristoyl) and/or in the chemical
nature of the anionic headgroup (serine or glycerol). Fig. 4 shows
binding isotherms for PLM38–72 and pPLM38–72 titrated with 2:1
DOPC/DOPS, 2:1 DMPC/DOPS and 2:1 DMPC/DOPG. Although the two
peptides had different afﬁnities for the three membrane systems, in
each case phosphorylation resulted in a large reduction in the afﬁnity
for the membranes (Table 1). Titration of the phosphorylated peptide
with the physiologically representative 9:1 DOPC/DOPS membranes
resulted in no detectable heat ﬂow (data not presented), indicating
that membrane interactions did not occur or were very weak.
CD spectroscopic measurements on PLM38–72 and pPLM38–72
(Fig. 5a and b, open circles) indicate that both peptides are essentially
unfolded in pure aqueous solution. CD spectra of PLM38–72 titrated
with 2:1 DOPC/DOPS, 2:1 DMPC/DOPS or 2:1 DMPC/DOPG vesicles (at
a lipid/peptide molar ratio of 75:1) are consistent in each case with an
increase in the helical content of the peptide (Fig. 5a and Table 2). The
membrane surface appears to stabilize the peptide in an amphipathic
helix, as reported elsewhere [19,21–23], although in each case the
estimated helical content is less than 10% (Table 2). By comparison,
the peptide is approximately 13%α-helix after titration of the solution
with 40% triﬂuoroethanol (TFE), which promotes intramolecular
hydrogen bonding and favors α-helical formation where an intrinsic
propensity for it exists. Interestingly, the DMPC/DOPS membranes
appear to induce a higher proportion of α-helix in PLM38–72 than do
the other membranes, suggesting that the peptide is sensitive to the
chemical structure of the lipid head-groups and the acyl chains. By
contrast, pPLM38–72 remains essentially unfolded in the presence of
the same membrane systems and TFE under identical conditions
(Fig. 5b and Table 2). The phosphorylated peptide thus has a lower
propensity to form a helix in the presence of a saturating
concentration of vesicles.
3.2. Afﬁnity of Mat-8 and CHIF peptides for phospholipid bilayers
Experiments were undertaken to measure themembrane afﬁnity of
peptides derived from the cytoplasmic domains of Mat-8 (Mat-838–67)issociation constant (KDapp) from ITCmeasurements of phospholipid membranes titrated
ce not all the lipid surface is available to the peptide for binding [32].
pPLM38–72
Χbsat (mol/mol) KDapp (M−1)
Not measured
107 0.111 (0.073) 1.83 (0.77)×10−5
Not measured
Not measured
10−6 0.102 (0.037) 1.63 (0.64)×10−5
10−6 0.282 (0.033) 1.56 (0.20)×10−5
lue and KDapp was not determined.
rentheses.
Fig. 4. Effect of PLM38–72 phosphorylation on membrane afﬁnity. ITC binding isotherms
are shown for PLM38–72 (open triangles) or pPLM38–72 (ﬁlled triangles) titrated with 2:1
DOPC/DOPS (a), 2:1 DMPC/DOPS (b) or 2:1 DMPC/DOPG (c). Solid lines represent the
best ﬁts to the data obtained with Eq. (2).
Fig. 5. Far UV CDmeasurements of PLM peptide secondary structure. Spectra are shown
for 50 μM PLM38–72 (a) and pPLM38–72 (b) in 10 mM phosphate, pH 7, alone (open
circles) or in the presence of 2:1 DMPC/DOPG vesicles (ﬁlled squares), 2:1 DMPC/DOPS
(ﬁlled circles) or 2:1 DOPC/DOPS (triangles) at a 75:1 lipid/peptide molar ratio. Note
that the signal for the DOPC/DOPS sample has been truncated below 205 nm because
these lipids gave rise to scattering effects at lower wavelengths.
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the arginine-rich sequence of PLM (Fig. 1). ITC measurements were
performedon thepeptides titratedwitheitherDOPCor2:1DMPC/DOPG
vesicles. No heat ﬂow was detected when CHIF38–69 was titrated with
either of these vesicles, indicating that no binding occurred or else that
the interaction was too weak to observe (data not presented). Similarly
noheatﬂowwasdetected in the titration ofMat-838–67withDOPC, but a
small endothermic reaction occurred for Mat-838–67 titrated with
DMPC/DOPG (Fig. 6a). Analysis of the binding isotherm indicated that
the binding was very weak, with KDapp in the millimolar range, although
the errors were rather large owing to the small endothermic response.
CD analysis indicated that Mat-838–67 is unstructured in aqueous
solution and only minor structural changes occur in the presence of
DMPC/DOPG membranes (Fig. 6b). The Mat-8 and CHIF cytoplasmic
domains thus have substantially lower membrane afﬁnities than the
PLM cytoplasmic domain. The NMR-determined structure of CHIF
incorporated into oriented lipid bilayers of 4:1 DOPC/DOPG placesTable 2
Estimates of percentage α-helix for PLM38–72 and pPLM38–72 calculated from CD molar
ellipticity values measured at 222 nm according to Eq. (1). Spectra were measured in
the presence of 40% TFE or lipid SUVs at a 75:1 lipid/peptide molar ratio.
PLM38–72 pPLM38–72
Water 3.8 1.7
TFE 13.4 3.3
2:1 DMPC/DOPG 6.4 2.4
2:1 DMPC/DOPS 8.9 2.7
2:1 DOPC/DOPS 2.7 2.8
Fig. 6. Measurements of Mat-838–67 interactions with 2:1 DMPC/DOPG membranes. (a) ITC heat ﬂows for 100 μM Mat-838–67 titrated with lipid vesicles (25 to 50 μM lipid per
injection). The inset shows the raw enthalpic data. (b) Far UV CDmeasurements of 50 μMMat-838–67 in 10 mMphosphate, pH 7, alone (open circles) or in the presence of 2:1 DMPC/
DOPC vesicles (ﬁlled squares) at a 75:1 lipid/peptide molar ratio.
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axis perpendicular to themembrane surface [42,43]. Thismodel, viewed
in the light of our results, implies that the CHIF cytoplasmic domain lies
close to the surface of the membrane but is not in contact with the lipid
headgroups.Fig. 7. 13C SSNMR experiments (at 4 °C) to detect interactions between PLM38–72 and
phospholipid membranes. (a) A 13C CP-MAS SSNMR spectrum of 2:1 DMPC/DOPG
membranes containing [13C]PLM38–72 at a 20:1 lipid/peptide molar ratio (top) and a 13C
NMR spectrum (with direct polarization) of [13C]PLM38–72 alone in phosphate buffer
(bottom). The peak at 156.6 ppm is characteristic for the guanidinium carbons (Cζ) of
arginines R61, R65, R66 and R67 is labeled Rζ. (b) 13C peak intensities for Rζ in CP-MAS
SSNMR spectra of [13C]PLM38–72 in 2:1 DMPC/DOPG membranes (top) and 2:1 DMPC/
DOPC membranes (bottom) at the variable contact times shown.3.3. SSNMR measurements of PLM38–72–membrane interactions
CP-MAS NMR can provide detailed information about the nature of
peptide-membrane interactions if signals are observed from 13C labels
placed at strategic sites in the peptide. Here, a spectrum of 2:1 DMPC/
DOPG membranes with [13C,15N]PLM38–72 at 30 °C displays a signature
peak from the arginineguanidiniumgroupsof thepeptide at156.6 ppm,
which is distinct from thebackgroundpeaks from the lipids (Fig. 7a, top)
and present in the solution spectrumof thepeptide (Fig. 7a, bottom)but
absent from the CP-MAS spectrum of lipid only. The presence of this
peak conﬁrms that the peptide associates with the negatively charged
membranes and that the cationic arginine side groups are motionally
restrained. Fig. 7b (top) shows that the guanidinium peak intensity
reaches amaximum at a contact time of around 6 ms, which is expected
for a nonprotonated carbon in a restrained environment [44]. By
contrast, no signals can be seen for [13C,15N]PLM38–72 in the presence of
2:1 DMPC/DOPC membranes under identical conditions (Fig. 7b,
bottom) indicating that the arginine groups are not restrained by the
zwitterionic lipids.
Further SSNMR experiments investigated whether PLM38–72 is able
to interact with the lipids of a native kidney membrane preparation
containingNKAandother integralmembraneproteins. The composition
of kidney membranes is approximately 0.87 mg phospholipid per mg
protein [45], of which ~19% are anionic [41], and the method described
in Fig. 7 is unsuitable because it cannot distinguish between peptide–
lipid and peptide–protein interactions. Instead, 13C(31P)-REDOR SSNMR
was used to determine whether the cationic arginine residues of [13C]
PLM38–72 lie close to the negatively charged phosphate group of the
lipids in frozen kidneymembranes (see Refs [46,47] for recent examples
of similar experiments). Fig. 8a shows a control full-echo 13C(31P)-
REDORdifference spectrumof [13C]PLM38–72 in kidneymembranes at an
approximately 20:1 lipid/peptide molar ratio. A difference spectrum
(Δ), obtained by subtracting a dephased spectrum from the control,
highlights dephasing of the guanidiniumsignal at 156.6 ppm, indicating
that one or more of these groups must be situated close to the lipid
phosphate groups. It is not possible to determine accurate peptide–lipid
distances from these data, but calculations based on an isolated 31P-13C
spin pair predict that one or more of the labeled arginine groups lie
within ~6 Å of the membrane surface to give rise to detectabledephasing under the conditions of this experiment. Additional experi-
ments at longer dephasing times were not attempted because the
limited sample size, unfavorable relaxation and poor sensitivity
Fig. 8. 13C[31P]-REDOR SSNMR experiments (at−30 °C) to detect interactions between
PLM38–72 and phospholipids in kidney membranes. (a) Spectra of kidney membranes
with PLM38–72 at a lipid/peptide molar ratio of approximately 20:1. The full-echo
spectrum is shown above the difference spectrum (Δ) obtained as described in the
Experimental section. (b) Full-echo (top) and difference (bottom) 13C[31P]-REDOR
spectra of 2:1 DMPC/DOPG membranes with PLM38–72 at a 20:1 lipid/peptide molar
ratio. The difference spectra are expanded vertically either 4-fold (×4) or 8-fold (×8).
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ment for [13C]PLM38–72 in DMPC/DOPG membranes showed much
stronger dephasing of the arginine guanidiniumsignal at ~160 ppmand
also signals corresponding to side group carbons (Rβ/γ/δ) at ~30 ppm
and to carbonyl carbons (C′) at ~170 ppm (Fig. 8b). This experiment
thus indicates that the peptide can interact with phospholipid head-
groups in the presence of NKA, but either the contact is less intimate or a
smaller fraction of the peptide is associated with the headgroups
compared with the pure lipid membranes.Fig. 9. Effects of PLM peptides on ATP hydrolysis by NKA in kidney membrane
preparations. (a) Activation of ATP hydrolysis by Na+ in the presence of PLM peptides.
Kidney NKA activity was determined at the indicated concentrations of Na+ in the
presence of 20 mM KCl, 3 mM ATP, 4 mM MgCl2 (pH 7.4 at 37 °C) and 100 μM peptide.
Control NKA (absence of peptide), ﬁlled squares; PLM63–72, open diamonds; PLM1–12
open squares; pPLM38–72, open down-triangle; PLM38–72, open circles. The full lines
represent non-linear least-squares ﬁts to a Hill equation with the parameters for Vmax,
K0.5 and Hill coefﬁcient n shown in Table 3. Mean values from 3 measurements are
shown at each Na+ concentration. Error bars are included but do not extend beyond the
symbols and are not visible. (b) Activation of ATP hydrolysis by Na+ in the presence of
100 μM Mat-838–67 (diamonds) or 100 μM CHIF38–69 (circles).3.4. Regulation of NKA by FXYD peptides
The sodium-dependence of the ATPase activity was measured in
presence of PLM38–72 and pPLM38–72 at a peptide concentration of
100 μM, and in the absence of peptide. Residues 38–72 of full length
PLM are conﬁned within a hemispherical space at the surface of the
two-dimensional lipid matrix and thus the local concentration
exposed to NKA is high. A high concentration of PLM38–72 wastherefore chosen to compensate for the free diffusion of the soluble
peptide in the large relative volume of the aqueous phase [48].
Fig. 9a shows the sodium-dependence of the ATPase activity in the
presence of 20 mM KCl. Control enzyme is half-maximally activated
by K0.5=13.5 mM NaCl, with maximal activity (Vmax) obtained at
about 100 mM NaCl (see also Table 3). The activity data, which
represent one of three experiments on freshly prepared enzyme and
peptide samples, are analyzed using a Hill equation:
V = V max& Na
þh in
= K0:5n + Na
þh in  ð3Þ
fromwhich the kinetic parameters Vmax, K0.5 and the Hill coefﬁcient n
are obtained from non-linear least squares ﬁtting of the data
(summarized in Table 3). PLM38–72 decreases Vmax to 59±10% of
the control (pb0.05), and K0.5 for Na+ is increased to about 16 mM.
pPLM38–72 also reduces Vmax (to 79+3.9% of the control) but
inhibition of maximal activity is signiﬁcantly lower than is observed
for PLM38–72 (pb0.05). Interestingly, pPLM38–72 also increases K0.5 to
16 mM, implying that phosphorylation of the peptide partially
relieves inhibition of maximal enzyme activity but does not recover
the lowered sodium afﬁnity of NKA. The shorter peptide PLM63–72 has
no effect on Vmax and only leads to a small increase in K0.5 for Na+,
Table 3
Activation of NKA hydrolysis by Na+ in the presence of peptides derived from PLM. Data
in Fig. 9 were ﬁtted by a Hill-type equation (see text) and parameters for maximal
hydrolytic activity (Vmax, expressed as micromoles ATP hydrolyzed/mg per min at
37 °C) as well as the half-maximal activating concentration of Na+ (K0.5, expressed as
mM Na+) in the presence of 20 mM KCl were extracted. The sigmoidicity of the
activation curve is described by the Hill-coefﬁcient (n). Mean values for Vmax and K0.5
are calculated from 9 measurements for control, PLM38–72 and pPLM38–72 groups and 3
measurements for PLM1–12 and PLM63–72 groups. Standard errors are given in brackets.
Parameter Treatment
Control PLM38–72 pPLM38–72 PLM1–12 PLM63–72
Vmax 30.0 (1.8) 17.7 (3.0) 23.7 (1.2) 29.9 (2.1) 29.7 (2.1)
K0.5 13.5 (0.41) 15.9 (0.47) 16.0 (0.46) 14.0 (0.41) 14.2 (0.41)
n 1.7 1.8 1.8 1.6 1.7
χ2 24.8 9.6 11.7 15.9 25.3
R2 (×100) 99.8 99.8 99.8 99.9 99.5
Fig. 10. Effects of PLM peptides on nucleotide binding by NKA in kidney membrane
preparations. (a) Equilibrium binding of [14C]ADP to NKA in the presence of 100 μM
PLM38–72 (open circles) and in the absence of PLM38–72 (ﬁlled squares). Each ﬁlter
contains 0.05 mg protein. The full line through the control data (ﬁlled squares)
represent a single hyperbolic function with maximal binding capacities of about
0.14 nmol/0.05 mg protein and a dissociation constant for ADP of 0.43 μM (±0.04,
n=3). The full line through the PLM-data (open circles) represents a single hyperbolic
function with a dissociation constant for ADP of 0.73 μM (±0.09, n=3) together with a
linear component with a slope of 0.0042 (±0.0001, n=3) nmol ADP bound/0.05 mg
protein per μM ADP (see text). The maximal binding capacities for the speciﬁc binding
in this ﬁtting procedure was ﬁxed to the same as for control enzyme, 0.14 nmol/
0.05 mg protein. (b) Equilibrium binding of [14C]ADP to NKA in the presence of 100 μM
pPLM38–72 (open circles) and in the absence of pPLM38–72 (ﬁlled squares). The
dissociation constant for ADP is 0.70 μM (±0.19). Conditions are as in (a) but using
0.048 mg protein.
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rectly for the inhibitory effect, or else are needed to stabilize the 10
C-terminal residues in an inhibitory conformation. NKA activity is
also unaffected by the peptide PLM1–12 representing the extracellular
region containing the FXYD motif. Mat-8 and CHIF had no effect on
NKA activity at a 100 μM peptide concentration (Fig. 9b).
Fig. 10 shows the effect of PLM38–72 and pPLM38–72 on ADP binding
to NKA. In the presence of about 30 mMNaCl the dissociation constant
for ADP is about 0.4 μM (±0.04) for control NKA, and addition of
0.1 mM PLM38–72 or pPLM38–72 leads to a slightly weaker binding of
ADP (Fig. 10a and b). It is notable that the two peptides induce
additional binding of ADP, which is completely absent in control
enzyme (compare circles and squares in Fig. 10). The high afﬁnity
binding of ADP to NKA (E) is described by the classical scheme
E + A⇔EA
characterized by the equilibrium constant
Kd =
E½ ⋅ A½ 
EA½  : ð4Þ
The binding curve for control enzyme was ﬁtted by the single
hyperbolic function:
EA½  = EA½  max⋅ A½ 
Kd + A½ 
ð5Þ
The nucleotide binding capacity is about 2.8 nmol/mg protein with
equilibrium dissociation constant Kd for ADP of about 0.4 μM as found
before [29]. In the presence of PLM38–72 or pPLM38–72 the additional
component seen at the higher concentrations of ADP appears to be a
linear function of the ADP concentration (deﬁned by constant Kadd),
and the data are ﬁtted adequately by a function
EA½  = EA½  max⋅ A½ 
Kd + A½ 
+ Kadd • A½  ð6Þ
Non-linear least squares ﬁtting of this function to both sets of data
(keeping [EA]max=2.8 nmol/mg protein) shows that both peptides
increase the dissociation constant for ADP to about 0.7 μM(±0.10)with
an additional non-speciﬁc binding-capacity of about Kadd=0.084 nmol
ADP/mg protein per μMADP (±0.002). The additional component does
not show signs of saturation at the concentrations of ADP used here (up
to 45 μM) and can either be due to unmasked additional sites on
NKA or to interactions with PLM, which itself is adsorbed to the
NKA-membranes (and thus retained on the ﬁlters). This second
explanation is supported in part by ITC measurements of a 100 μM
PLM38–72 solution titrated with ADP (not presented), which showed
that the nucleotide binds to peptide in a 1:1 stoichiometry with adissociation constant of 7.8 μM and reaching saturation at approxi-
mately 160 μM ADP. The physiological relevance of this interaction is
unknown and is not investigated further here.
4. Discussion
4.1. Functional role of the PLM cytoplasmic domain
Several studies have demonstrated that PLM contributes to the
maintenance of normal cardiac function through the functional
modulation of NCX1 and NKA [4,15,49–53], although there is debate
as to whether PLM increases or reduces the ionic afﬁnity and maximal
activity of NKA [54,55]. In the heart, NKA is the primary mechanism of
Na+ extrusion, and a decrease in cardiac NKA activity post-myocardial
infarction and in heart failure [56–58] has been linked to PLM over-
expression and a down-regulation of NKA expression [57]. The patho-
physiological consequences of alterations in PLM expression may be
offset by the elevation of PLM phosphorylation [58] and/or phospha-
tase activity [59]. The cytoplasmic domain of PLM alone reduced
ouabain-sensitive sodium currents in PLM-depleted myocytes and
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ylated at S68 [15]. The nature of the NKA-PLM interaction in lipid
bilayers is unclear, and current models are based upon NMR structural
analysis of PLM alone in SDS micelles. In these models the cyto-
plasmic domain aligns parallel with the membrane surface and thus
interacts with NKA at the interface with the lipid headgroups [20].
These latter observations provide an incentive to study in more detail
the cytoplasmic C-terminal region of PLM, focusing on how phospho-
rylation modulates its interactions with lipid membranes and
with NKA.
4.2. Membrane interactions of the PLM cytoplasmic domain
With the peptide PLM38–72 the membrane surface interactions of
the PLM cytoplasmic domain were investigated in isolation from the
remainder of the protein. The C-terminal region of PLM38–72 is rich in
arginine residues and is thus highly basic, and our earlier work
showed that the peptide binds as an amphipathic helix to anionic
phospholipid surfaces [23]. Here, ITC experiments provide a more
quantitativemeasure of themembrane afﬁnity of PLM38–72 before and
after phosphorylation. As expected, the peptide has the highest
afﬁnity for the most negatively charged membranes (i.e., consisting of
over 50% anionic phospholipids). This agrees with the NMR structural
model of PLM in anionic SDS micelles, in which the cytoplasmic
domain aligns along the charged micelle surface. The membrane
afﬁnity of PLM38–72 is reduced substantially after phosphorylation at
S68. This contrasts with NMR studies of full-length PLM in SDS
micelles, which indicate that phosphorylation does not alter signif-
icantly the position of the cytoplasmic domain at the membrane
surface. In the latter case, the transmembrane domain of PLM may
help to anchor the cytoplasmic domain to the membrane surface.
Importantly, PLM38–72 has a substantially weaker interaction with
membranes carrying ~10% anionic phospholipids, which is more
representative of the native membrane environment. The physiolog-
ical effect of phosphorylation on an already weak membrane
interaction may therefore be insigniﬁcant. Furthermore, although
the membrane afﬁnities of the Mat-8 and CHIF cytoplasmic domains
are much lower than seen for PLM38–72 in our model systems, this
distinction may be less pronounced in the native membrane
environments if the membrane afﬁnity of PLM38–72 is also low.
4.3. Effect of FXYD cytoplasmic peptides on NKA function
PLM38–72 regulates NKA activity in a membrane preparation from
kidney, by lowering slightly the afﬁnity of the enzyme for sodium
and depressing (by ~30%) the maximal ATPase activity at saturating
sodium concentrations (Fig. 9). The reduced afﬁnity of NKA for
nucleotide in the presence of the peptide (Fig. 10) suggests that
there may be some overlap in the peptide and nucleotide binding
sites on the cytoplasmic face of the enzyme. This interpretation
should be treated with caution, however, because a decrease in Kd
for ADP could also occur if PLM acts as K+ (inducing the E2-form).
From the activity data we also see a requirement for more Na+ for
activity, which in a simpliﬁed analysis means the same thing, namely
that PLM pushes NKA towards the E2-form. Phosphorylation of
PLM38–72 at S68 partially (but statistically signiﬁcantly) reverses the
effect of the peptide on Vmax but does not alleviate the lower afﬁnity
for sodium. The effect of the peptides on sodium afﬁnity parallels the
nucleotide afﬁnity of NKA, which is reduced by a similar amount by
both PLM38–72 and pPLM38–72. That phosphorylation of PLM38–72
affects Vmax but not the sodium or nucleotide afﬁnity of NKA
suggests that the peptide affects one or more stages of the catalytic
cycle of NKA following binding of sodium or ATP.
Interestingly, Mat-838–67 and CHIF38–69 do not have any apprecia-
ble effect on NKA activity, suggesting that the cytoplasmic domains of
Mat-8 and CHIF have quite different functional characteristics to thoseof PLM. We speculate that one explanation for this distinction is that
PLM is a known phosphorylation substrate whereas Mat-8 and CHIF
are not. Phosphorylation may therefore serve as a functional switch in
the PLM cytoplasmic domain, but Mat-8 and CHIF have evolved
functionally inert cytoplasmic domains for which phosphorylation
would be redundant.
5. Conclusions
This work has found that the membrane interaction of the PLM
cytoplasmic domain is highly dependent on the lipid headgroup
composition, and that the interaction with membranes containing
physiological amounts of anionic phospholipids is rather weak.
Structural models of the PLM/NKA interaction based on NMR
measurements on anionic detergent micelles suggest that the
cytoplasmic domain is retained at the membrane surface [19,21,22].
The highly chargedmicellar environmentmay not in this instance be a
suitable proxy for a cell membrane bearing a much lower surface
charge. We suggest a reﬁnement to the recently proposed models,
which allows PLM to populate several orientational and structural
states in dynamic equilibrium. At one extreme the PLM cytoplasmic
domain may orient approximately perpendicularly to the transmem-
brane region as depicted in the NMR models [19,21,22]. We
hypothesize that the cytoplasmic domain is also free to move away
from the membrane to a more upright orientation in contact with the
NKA cytoplasmic domain close to the nucleotide site. Such an
orientation could account for the effect of PLM38–72 on the sodium
and nucleotide afﬁnity of NKA. The effect of PLM phosphorylation on
such a dynamic equilibrium is not known; phosphorylation reduces
the afﬁnity of the cytoplasmic domain for highly anionic lipid
membranes, but this may have little overall effect in physiological-
ly-charged membranes where the membrane afﬁnity is already weak.
Phosphorylation at S68 does not alter the depressed nucleotide and
sodium afﬁnity of NKA, yet phosphorylation alleviates the effect on
Vmax and also reduces the propensity of the PLM cytoplasmic domain
to adopt an α-helical structure in 40% TFE. Together these observa-
tions suggest that phosphorylation of PLM has greater consequences
for NKA-PLM interaction than for the interactions of PLM with the
membrane surface.
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